Onabotulinumtoxin A and sacral neuromodulation are options for treating women with refractory urge urinary incontinence. Both of these treatment options provide symptomatic relief and have advantages and drawbacks. Discussion with patients regarding the risks and benefits of each therapy is critical for informed treatment choice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Amundsen, C. L. et al. OnabotulinumtoxinA versus sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA 316, 1366–1374 (2016).
Tincello, D. G. et al. Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomized blinded placebo-controlled trial of 240 women (the RELAX study). Eur. Urol. 62, 507–514 (2012).
van Voskuilen, A. C., Oerlemans, D. J., Weil, E. H., van den Hombergh, U. & van Kerrebroeck, P. E. Medium-term experience of sacral neuromodulation by tined lead implantation. BJU Int. 99, 107–110 (2007).
Siegel, S. et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol. Urodyn. 34, 224–230 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.D. has been a consultant for Allergan and Medtronic.
Rights and permissions
About this article
Cite this article
Dmochowski, R. Treating women with refractory urge urinary incontinence. Nat Rev Urol 14, 11–12 (2017). https://doi.org/10.1038/nrurol.2016.244
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.244
